Stevanato Group S.p.A. (FRA:87N)

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
EMEA Revenue	692.77M	667.83M
APAC Revenue	101.03M	96.24M
North America Revenue	321.83M	308.95M
South America Revenue	29.47M	31.02M
Revenue (Other)	-	1,000.00
Revenue (Total)	-	1.10B

Revenue

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Revenue	976.82M	933.74M
Engineering Revenue	168.28M	170.29M
Revenue (Total)	-	1.10B

Gross Profit

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Gross Profit	298.47M	268.78M
Engineering Gross Profit	47.14M	56.17M
Eliminations from Gross Profit	-24.54M	-22.63M
Gross Profit (Total)	-	302.32M

EBIT

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Operating Profit	193.51M	165.64M
Engineering Operating Profit	28.95M	33.10M
Eliminations from Operating Profit	-38.58M	-37.59M
Operating Income (Total)	-	161.14M

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Backlog	853.00M

Updated Jun 30, 2025. Data Source: Fiscal.ai.